Key Points
The biotech published an earnings report that fell short of expectations.
It whiffed on both the top and bottom lines.
10 stocks we like better than Roivant Sciences ›
Commercial-stage biotech Roivant Sciences (NASDAQ: ROIV) started the trading week with an earnings release. In retrospect, that might not have been the wisest move. Following Monday morning’s unveiling of its fiscal first-quarter release, investors generally traded out of the stock. It had slid by more than 3% in late-session trading at a point when the S&P 500 index was only down marginally.
Falling short
Roivant reported that its revenue for the period was slightly under $2.2 billion, which was quite some distance down from the nearly $8 billion it reaped in the same quarter last year. The situation was hardly better on the bottom line, as the company flipped to a more than $223 million ($0.33 per share) generally accepted accounting principles (GAAP) net loss from the year-ago profit of $95 million.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
Compounding that, neither result met analyst expectations. The consensus pundit projection for revenue was far higher, at almost $7.7 billion, while that for net loss was narrower ($0.25).
Roivant did not provide details for its financial line items either in its earnings release or the 10-Q quarterly-earnings statement it filed with the Securities and Exchange Commission (SEC); this somewhat black-box quality might have contributed to the negative investor reaction.
An industry outlier
Roivant is atypical even for the extremely varied biotech sector in that it divides its business into “vants” — subsidiaries — based on a specific medication or cluster of drugs. Over time, some of these have been sold to business partners in order to raise capital.
Regarding that subject, Roivant said that it had cash, equivalents, restricted cash, and marketable securities amounting to roughly $4.5 billion. That was down from the nearly $4.9 billion in the year-ago quarter.
Should you invest $1,000 in Roivant Sciences right now?
Before you buy stock in Roivant Sciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Roivant Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $653,427!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,119,863!*
Now, it’s worth noting Stock Advisor’s total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 11, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy.
